Propafenone and a Syndrome of the Lupus Erythematosus Type
Authors: Josep Guindo, Arturo Rodriguez De La Serna, Javier Borja, Ramón Oter, Francisco Jané, Antonio Bayés De Luna
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 April 1986Propafenone and a Syndrome of the Lupus Erythematosus TypeJOSEP GUINDO, M.D., ARTURO RODRIGUEZ DE LA SERNA, M.D., JAVIER BORJA, M.D., RAMÓN OTER, M.D., FRANCISCO JANÉ, M.D., ANTONIO BAYÉS DE LUNA, M.D.JOSEP GUINDO, M.D.Search for more papers by this author, ARTURO RODRIGUEZ DE LA SERNA, M.D.Search for more papers by this author, JAVIER BORJA, M.D.Search for more papers by this author, RAMÓN OTER, M.D.Search for more papers by this author, FRANCISCO JANÉ, M.D.Search for more papers by this author, ANTONIO BAYÉS DE LUNA, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-104-4-589 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Drug-induced lupus erythematosus is characterized by a wide spectrum of clinical symptoms, ranging from mild arthralgias to systemic involvement, although photosensitivity and the presence of serum antinuclear antibodies against histone antigens may also be seen. These reactions are produced by many drugs (1, 2), some of which are antiarrhythmics, mainly procainamide. We report a case showing the new association of a syndrome with features of lupus erythematosus associated with another antiarrhythmic drug, propafenone.A 63-year-old woman with a history of coronary heart disease and arterial hypertension had been treated for more than 6 months with nifedipine, 30...References1. WEINSTEIN A. Drug-induced systemic lupus erythematosus. Prog Clin Immunol. 1980;4:1-22. MedlineGoogle Scholar2. MORLEYHUGHES KG. Systemic lupus erythematosus: causative factors and treatment. Drugs. 1982;23:481-8. CrossrefMedlineGoogle Scholar3. GRABOYSLOWNPODRIDDA SILVA TBPC. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol. 1982;50:437-48. CrossrefMedlineGoogle Scholar4. GUINDOBAYÉS DE LUNABORJA JAJ. Evaluación terapéude las arritmias ventriculares mediante el test agudo incruento modificado. Rev Esp Cardiol. 1985;35(suppl 2):37-8. Google Scholar5. DE SOYZAMURPHYSAKHAIITREAT NMML. The safety and efficacy of propafenone in suppressing ventricular ectopy. In: SHLEPPER M, OLSSON B, eds. Cardiac Arrhythmias. Berlin: Springer-Verlag; 1983:217-9. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPropafenoneDiagnosis and classification of drug-induced autoimmunity (DIA)Adverse immunological effects of drugs other than anticance drugs and drugs used in immunologyANTIDYSRHYTHMIC DRUGSPropafenonePropafenone-induced acute generalized exanthematous pustulosisAdverse Dermatologic Effects of Cardiovascular Drug Therapy: Part IPropafenone-Induced Peripheral NeuropathyAdverse Dermatologic Reactions from Antiarrhythmic Drug TherapyPropafenone: A Promising New Antiarrhythmic AgentThe Thermal Decomposition of Carbohydrates. Part I. The Decomposition of Mono-, Di-, and Oligo-SaccharidesDrug-Related LupusPositive inotropic drugs and drugs used in dysrhythmiasManagement of Cardiac Arrhythmias 1 April 1986Volume 104, Issue 4Page: 589-589KeywordsAntigensAntinuclear antibodiesArthralgiaCoronary heart diseaseDrugsHistonesHypertensionLupus erythematosus Issue Published: 1 April 1986 PDF DownloadLoading ...